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Abstract
Background: An association has been found between multi-dose drug dispensing (MDD) and use of many drugs. The aim of
this study was to investigate the nature of this association, by performing a longitudinal analysis of the drug treatment
before and after the transition to MDD.
Methods: Inclusion critera in this register-based study were inhabitants in Region Va¨stra Go¨taland, Sweden, who, at $65
years of age and between 1st July 2006 and 30th June 2010, filled their first MDD prescription. For each individual, prescribed
drugs were estimated at three month intervals before and after (maximum 3 years, respectively) the first date of filling an
MDD prescription (index date).
Results: A total of 30,922 individuals matched the inclusion criteria (mean age: 83.2 years; 59.9% female). There was a
temporal association between the transition to MDD and an increased number of drugs: 5.463.9 and 7.563.8 unique drugs
three months before and after the index date, respectively, as well as worse outcomes on several indicators of prescribing
quality. When either data before or after the index date were used, a multi-level regression analysis predicted the number of
drugs at the index date at 5.76 (95% confidence limits: 5.71; 5.80) and 7.15 (7.10; 7.19), respectively, for an average female
individual (83.2 years, 10.8 unique diagnoses, 2.4 healthcare contacts/three months). The predicted change in the number of
drugs, from three months before the index date to the index date, was greater when data before this date was used as
compared with data after this date: 0.12 (0.09; 0.14) versus 0.02 (20.01; 0.05).
Conclusions: After the patients entered the MDD system, they had an increased number of drugs, more often potentially
harmful drug treatment, and fewer changes in drug treatment. These findings support a causal relationship between such a
system and safety concerns as regards prescribing practices.
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Introduction
Although dose dispensing systems are widespread over the
world [1], scientific evidence is scarce [2,3]. Indeed, beneficial
effects have not been proven [3], illustrated, for example, by the
inconsistent results for effects on compliance [4,5]. On the
contrary, recent research has indicated safety concerns regarding
the prescribing of drugs to patients within such systems. For
example, the odds for potentially harmful drug treatment
according to polypharmacy indicators were 3.58 ($10 drugs) to
5.48 ($3 psychotropics) times greater for patients aged $65 years
within the Swedish multi-dose drug dispensing (MDD) system,
after adjustments for age, sex, burden of disease, and residence [6].
Furthermore, drug orders were more seldom changed within this
MDD system [7], a finding which indicates that such systems may
diminish physicians’ reconsideration of drug treatment. In
addition, medication errors have been reported to be almost six
times as common in older patients with MDD [8].
If there is a causal relationship between MDD and potentially
harmful drug treatment, this is alarming since the prescriber rather
than the nursing and pharmacy services accounts for the majority
of severe medication errors [9]. However, no conclusions on
causality can be drawn since previous controlled studies, to the
best of our knowledge, have applied a cross-sectional or a case-
control design. Although a randomized controlled design may be
preferable when to evaluate causality, this kind of design may not
be feasible when it comes to the effects of MDD on prescribed
drugs. Indeed, an MDD system may be already implemented. In
Sweden, for example, about eleven per cent of people aged $65
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years use such a system (described elsewhere) [7], because they
have difficulties in handling their drugs due to impaired physical
or cognitive function.
A strategy to further investigate the association between MDD
and drug treatment may be to analyze drug treatment over time in
register data, i.e. a longitudinal analysis on the individual level
encompassing time before and time after the transition to MDD.
Indeed, such a strategy may be an alternative to a randomized
controlled design when the latter is not feasible. Thus, the aim of
the present study was to analyze drug treatment over time in
individuals, aged $65 years, before and after they entered an
MDD system.
Materials and Methods
Ethics Statement
All data in the registers at question are recorded without written
consent from the patients. Before data were extracted for the
purpose of this study, approval was obtained from the Regional
Ethical Review Board in Gothenburg, which waived informed
consent (Dnr: 782-11).
Data Extraction
Data for the present study were extracted from three individual-
based registers, and linked by the unique personal identity
number: the Swedish Population Register at the Statistics Sweden,
the Swedish Prescribed Drug Register at the National Board of
Health and Welfare, and Vega (a regional register including
healthcare consumption and diagnoses according to the Interna-
tional Statistical Classification of Diseases and Related Health
Problems, ICD-10). The study comprised data from 1st July 2005
to 31st December 2010 (study period).
Study Population
The study population was extracted from individuals residing in
the Region Va¨stra Go¨taland at any time during the study period.
All individuals who entered the MDD system between 1st July
2006 and 30th June 2010 at the age of $65 years were included.
Thus, at least one year with drugs prescribed by ordinary
prescriptions was ascertained (1st July 2005 to 30th June 2006),
as well as a follow-up of at least six months after the transition to
MDD. Since data on burden of disease was obtained from a
regional register, individuals who moved into/out of this region
during the study period were excluded. Individuals whose personal
identity number had been used before were also excluded to avoid
mismatching between registers.
Drug Treatment
All estimations of drug treatment were performed according to
an established method [10] that is also employed by the National
Board of Health and Welfare. In short, the method implies that a
medication list is constructed for each measure date (Figure 1). For
each individual, the first date of filling an MDD prescription was
defined as the index date. Drug treatment was evaluated at three
month intervals before and after this date, up to 36 months,
respectively. After the index date, individuals were censored, if
applicable, when they returned to ordinary prescriptions and at
death.
Before the index date, the patients received their drugs via
ordinary prescriptions. At each measure date, a medication list was
constructed according to the filled prescriptions registered in the
Swedish Prescribed Drug Register during the three month period
preceding the date in question. The register was initiated on 1st
July 2005 and, thus, the earliest measure date was 30th September
2005. The rationale for the three month time frame was Swedish
regulations, which allow drug use for a maximum of three months
to be reimbursed at one purchase occasion. To assess if a drug was
to be included in the medication list, i.e. if the purchase covered
treatment at a specific measure date, we used (i) the date of filling
the prescription, (ii) the amount of drug dispensed, and (iii) the
prescribed dosage. When prescribed dosage was incomplete or
missing, the mean daily dose for the specific drug in the study
population was used. For drugs prescribed as needed we assumed
a dosage of 50% of that for regular drugs. Moreover, we assumed
a daily dose of 1 defined daily dose (DDD) [11] for drugs for
external use and for the eye. Drugs were aggregated at the
substance level of the Anatomical Therapeutic Chemical (ATC)
classification system (7 digits) [11].
Within the MDD system, prescribed drugs are either dispensed
into unit bags with prescriptions filled every fortnight, or delivered
in original packages. Therefore, from the index date and onwards,
we included dose-dispensed drugs in the medication list if filled
within 14 days before the measure date in question. For drugs
delivered in whole packages (about 50% of drugs prescribed vid
the MDD system) [12], we included drugs in the medication list
according to the method described above for ordinary prescrip-
tions. As the Swedish Prescribed Drug Register does not include
prescribed dosages for patients with MDD, we assumed the
prescribed dosage to be the mean daily dose in the population.
To further explore the changes in prescribed drugs that occur at
the transition to MDD, the medication list of each measure date
was evaluated according to indicators of prescribing quality used
by the Swedish National Board of Health and Welfare, that is, use
of Ten or more drugs, Three or more psychotropics, Long-acting
benzodiazepines, Drugs with anticholinergic effects, Drug combinations that
should be avoided [13], and Antipsychotics (Table 1). Moreover, a
descriptive analysis of the medication list was applied to the
subgroup of patients still filling MDD prescriptions three months
after the index date. In this analysis, we identified the drugs which
were most frequently added to the medication list at the index
date.
Burden of Disease
In order to investigate the longitudinal health course of a
patient, the number of unique diagnoses (ICD-10-diagnoses, 3
digits) in hospital and primary care were summarized cumulatively
for each individual at three month intervals. Only codes starting
with A to T were included. Hence, we excluded codes starting with
V to Y (external causes of morbidity and mortality), Z (factors
influencing health status and contact with health services), or U
(codes assigned for special purposes). At the first measure date,
unique diagnoses were extracted from the year preceding this date.
For the following measure dates, additional unique diagnoses were
counted and added. In addition, we identified the hospital
diagnoses which most frequently preceded the transition to the
MDD system. The longitudinal health course was also investigated
by extracting the number of healthcare contacts during which
prescribing changes primarily occur, that is, hospital admissions as
well as physician contacts in outpatient care.
Statistical Analysis
The data were handled using SAS Enterprise Guide 4.3 (SAS
Institute Inc, Cary, NC, USA), and the statistical analyses were
performed using SPSS 17.0 (SPSS, Chicago, IL, USA). A
descriptive longitudinal analysis was performed regarding the
drug treatment, the number of unique ICD-10 diagnoses, and the
number of healthcare contacts. We also analyzed the proportion of
the patients at each measure date who had the same number of
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drugs at that specific date compared with the previous one. Multi-
level regression models were constructed to predict the total
number of drugs at the index date as well as the change in the
number of drugs between the measure date preceding the index
date and the index date. Each measure date represented level 1
and individuals were level 2. The parameter estimates were based
on data before or after the transition to MDD, respectively.
Hence, in order to predict results at the index date, a prediction
forwards was made for the data before the index date, and a
prediction backwards for the data after this date. In order to allow
the figures obtained at this date to represent the results for an
average individual, that is, an individual of mean age with the
Figure 1. Illustration of the method used to estimate the medication list. A medication list was estimated at the transition to multi-dose
drug dispensing (MDD) as well as at up to 12 measure dates before and after this date, respectively, with three month intervals. For drugs purchased
in whole packages (prescribed via ordinary prescriptions or MDD) at any time during the three month period preceding the measure date (light grey
bar), the duration of treatment with the drug was estimated according to (i) the date of filling the prescription, (ii) the amount of drug dispensed, and
(iii) the prescribed daily dose, or, if not available, the mean daily dose in the study population. If the duration of the drug covered the measure date,
the drug was included in the medication list, i.e. drug a, but not drug b. Concerning drugs prescribed via the MDD system and dispensed into units
bags, all drugs purchased within the time frame of the dark grey bar, but not the dotted one, were included in the medication list. *All drugs
prescribed vid ordinary prescription and about 50% of drugs prescribed via the MDD system [12] are delivered in whole packages.
doi:10.1371/journal.pone.0067088.g001
Table 1. Description of the indicators of prescribing quality.
Indicator Included drugs ATC-code1
Ten or more drugs All drugs
Three or more psychotropics Antipsychotics N05A
Anxiolytics N05B
Hypnotics and sedatives N05C
Antidepressants N06A
Long-acting benzodiazepines Diazepam N05BA01
Nitrazepam N05CD02
Flunitrazepam N05CD03
Drugs with anticholinergic effects (Anticholinergic) drugs for functional gastrointestinal disorders A03AB, A03BA, A03BB
(Anticholinergic) antiemetics A04AD
Antiarrythmics class Ia C01BA
Urinary antispasmodics G04BD
Opioids in combination with antispasmodics N02AG
Anticholinergic (anti-Parkinson drugs) N04A
Low potency antipsychotics N05AA, N05AB04, N05AF03
Hydroxyzine N05BB01
Non-selective monoamine reuptake inhibitors (antidepressants) N06AA
Antihistamins R05CA10, R06AA02, R06AB, R06AD, R06AX02
Drug combinations that should be
avoided
D-interactions according to the Swedish Physicians’ Desk Reference [13]
Antipsychotics Antipsychotics N05A
1ATC-code, Anatomical Therapeutical Chemical classification code [11].
doi:10.1371/journal.pone.0067088.t001
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mean number of unique ICD-10 diagnoses and the mean number
of healthcare contacts during the three month periods between the
measure dates, grand-mean centered values were calculated and
used in the models. The intercept was estimated with time in a
random effects model. The other covariates were included as fixed
main effects only. The maximum likelihood estimation procedure
was used to estimate the parameters of the models. To test whether
addition of another covariate improved the model, the difference
in -2log likelihood values was tested for chi-squared distribution.
Results
A flowchart of the study population is presented in Figure 2. A
total of 30,922 individuals were included in the analyses (mean
age6standard deviation (SD): 83.267.2 years; 59.9% female).
In all, drug treatment was estimated at 493,396 occasions, at a
maximum of 25 measure dates with three month intervals for each
individual. The patients were treated with up to 40 unique drugs
concomitantly. The longitudinal course of the number of unique
drugs and unique substances is presented in Figure 3A, along with
the cumulative number of unique ICD-10 diagnoses and the
number of healthcare contacts within each three month period. A
peak in the number of drugs was observed at the index date:
9.264.8 drugs and 8.064.0 substances, respectively. Three
months before and three months after the index date, the number
of unique drugs was 5.463.9 and 7.563.8, respectively. The
increase in the number of drugs was maintained during the follow-
up. The proportion of the individuals who, at three month
intervals, had the same number of drugs at a specific measure date
compared with the preceding one, is presented in Figure 3B.
In Figure 3C, the longitudinal results on indicators of prescribing
quality are presented. A peak in the proportion of individuals with
potentially harmful drug treatment at the index date as well as a
maintained elevated level thereafter was observed for Ten or more
drugs and Three or more psychotropics. A peak at the index date and a
subsequent dip to previous level or lower was observed for Longacting
benzodiazepines and Drug combinations that should be avoided. An increase
at the index date without a subsequent decline was observed for
Drugs with anticholinergic effects and Antipsychotics.
In all, 9,990 patients (32.3%) had received inpatient care within
14 days before the index date. The most frequently registered
ICD-10 diagnoses on these occasions were cerebral infarction, hip
fracture, heart failure, and myocardial infarction. A total of 8.9%
of all individuals had either of these diagnoses. Paracetamol,
furosemide, cyanocobalamin, omeprazole, and simvastatin were
the drugs most frequently added to the medication list when an
individual entered the MDD system (Figure 4).
Five multi-level regression models were constructed; each with
an additional covariate included (Table 2). Regarding the number
of drugs, but not the change in the number of drugs, the models
were significantly improved for each parameter that was added.
For an average female individual (83.2 years of age with 10.8
unique ICD-10 diagnoses and 2.4 healthcare contacts within three
month periods), the model predicted the number of drugs at the
index date, based on either data before or data after this date, at
5.76 (95% confidence limits: 5.71; 5.80) and 7.15 (7.10; 7.19),
respectively. This model also revealed that the predicted change in
the number of drugs, from three months before the index date to
the index date, was greater when data before this date was used as
compared with data after this date: 0.12 (0.09; 0.14) versus 0.02
(20.01; 0.05).
Discussion
In this longitudinal study, we show a temporal association
between the transition to MDD and an increased number of drugs
Figure 2. Flowchart of the study population. The study population was extracted from individuals residing in the Region Va¨stra Go¨taland at any
time during the study period (1st July 2005–31st December 2010).
doi:10.1371/journal.pone.0067088.g002
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in the medication list. Indeed, the patients received about two
more drugs after the transition, and this increase was maintained
throughout the follow-up. We also show that the patients more
often had potentially harmful drug treatment after they entered
the system. Multi-level regression analyses, adjusted for burden of
disease, age, and sex, confirm that the transition to MDD is
associated with an increased number of drugs. The initial addition
of drugs at the index date may be the most prominent underlying
factor for these results. Further, the temporal association between
the transition to MDD and an increased proportion of patients
with the same number of drugs at consecutive measure dates
indicates that the drug treatment may be more seldom reconsid-
ered within such a system. Indeed, the predicted change at the
index date (the number of drugs at the index date minus the
number of drugs three months before this date) was smaller when
data after the transition was used for the estimation.
The peak observed at the index date may, at least partly, be
explained by the definition of this date, which represents the date
of the first filled MDD prescription. Since such prescribing is
initiated by a physician, a clinical event that requires drug
treatment may precede the physician contact. Indeed, there was a
slight temporal increase in the slope of the curve regarding
number of unique diagnoses around the index date, probably
drawn by the increased number of healthcare contacts during this
period. In addition, the most common events preceding the index
date were diagnoses which may all may lead to the initiation of
drug treatment, for example cerebral infarction, hip fracture, heart
failure, and myocardial infarction. Indeed, cardiovascular drugs
and analgesics were among the drugs most frequently added to the
medication list when the patients entered the MDD system.
Our longitudinal findings support a causal relationship between
MDD and an extended medication list. Thus, we have further
characterized the association between MDD and polypharmacy,
which has been reported previously [6]. Furthermore, our results
imply causality between MDD and potentially harmful drug
treatment according to indicators of prescribing quality, where
non-characterized associations have been reported previously
[6,14,15,16]. This was most prominent for the indicators Ten or
more drugs, Three or more psychotropics, Drugs with anticholinergic effects
and Antipsychotics. In particular, the results on the quality indicator
Antipsychotics may call for attention, as well as the finding that
risperidone was one of the drugs most frequently added to the
medication list at the transition to MDD; these drugs have been
associated with an increased risk of death in people with dementia
[17].
A previous study reported that the odds for a drug to stay
unchanged during a six month period were greater if prescribed
via the MDD system than via ordinary prescriptions [7]. This
measure may be seen as a surrogate variable for drug treatment
reconsideration. Our results indicate a causal relationship between
MDD and fewer changes in drug treatment; after adjustments for
relevant covariates, the predicted change in the number of drugs at
the index date, compared with the preceding measure date, was
significantly smaller when data after the transition was used for the
estimations.
Figure 3. Longitudinal results for 30,922 individuals at three month intervals before and after the transition to multi-dose drug
dispensing (index date). (A) The mean number of unique drugs and substances (primary y-axis), the cumulative number of unique ICD-10-
diagnoses, and the number of healthcare contacts within each three month period (secondary y-axis). (B) The proportion of the patients without a
change in the number of drugs at a specific measure date compared with the previous one. (C) The proportion of the patients who had potentially
harmful drug treatment according to indicators of prescribing quality. The individuals were censored when they returned to ordinary prescriptions
and after death. The number of individuals included at each specific measure date is presented below the figures.
doi:10.1371/journal.pone.0067088.g003
Figure 4. ATC substances that increased by more than 1000 orders at the index date in individuals alive three months after the
index date still filling multi-dose drug dispensed prescriptions.
doi:10.1371/journal.pone.0067088.g004
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Underlying mechanisms for our findings can only be speculated
upon. Some previous studies indicate that an MDD system may
reduce medication errors [18,19] and provide a better overview of
a patient’s medication list [20,21]. Thus, it cannot be excluded
that the medication lists in the present study may be appropriate at
the individual level, although extended and more often potentially
harmful according to indicators. Other studies, on the other hand,
indicate the opposite, namely that medication errors are as
common or even more common for patients with MDD
[8,22,23,24]. Indeed, MDD was the main risk factors for
medication errors at transitions in healthcare [25]. Furthermore,
the experienced increased workload for general practitioners for
prescribing within such systems [20,21] may affect prescribing
practices and reduce reconsideration of drug treatment.
A strength of the present study is that is comprises all individuals
in our region who, at $65 years of age and during a four year
period, filled their first MDD prescription. The large number of
individuals, as well as the fact that few individuals were excluded,
makes it reasonable to generalize from the results. In addition, our
longitudinal approach to analyze drug register data linked to other
individual-based register data may represent a valuable tool to
further investigate causality hypotheses arisen from cross-sectional
and case-control studies, when randomized controlled studies are
not feasible. Indeed, our approach implies that each individual is
compared with his/herself, before and after the transition, and the
comparisons are thus made within a population, and not between
different populations. Hence, the risk of confounding by indication
is reduced. Moreover, in the multi-level regression analyses, we
have included covariates that are important for drug treatment,
that is, age, sex, and burden of disease, measured as the
cumulative number of unique diagnoses and the number of
healthcare contacts.
Limitations of this study include confounding by indication.
Although we have tried to minimize this problem, we cannot
exclude that the differences observed in the drug treatment at the
transition to MDD may be due to factors that have not been
considered in the analyses. Indeed, a new healthcare structure,
forcing every individual to choose a specific primary care provider,
was introduced in Sweden on 1st January 2010. Such healthcare
reforms may affect longitudinal results. However, the pattern of an
increased number of drugs at the transition to MDD was similar
when the results were analyzed according to year of transition
(data not shown). Further, we evaluated drug treatment in terms of
the number of drugs in the medication list and the outcomes on
indicators of prescribing quality. Thus, evidently, an added drug
may cancel out a withdrawn drug. Moreover, although the
indicators are established outcomes frequently used to describe
prescribing practices, the association with quality of drug
treatment at the individual level has not been established [26].
Thus, we do not know if the number of drugs or the indicators of
prescribing quality can differentiate between appropriate and
inappropriate drug treatment. Another limitation is that the
method for drug treatment estimations involves uncertainties. For
example, medications prescribed as needed may be consumed to a
greater or a smaller extent than 50% of the DDD, and may thus
not be captured correctly, e.g. epinephrine for treatment of
anaphylaxis.
Conclusion
This study indicates a causal relationship between the transition
to MDD and an increased number of drugs, potentially harmful
drug treatment, and a reduced reconsideration of drug treatment.
Thus, such a system may imply safety concerns regarding the
prescribing of drugs. The results should be of interest for health
care decision makers and prescribers in countries that already
have, or plan to introduce, dose dispensing systems and to people
who design the prescribing properties within these systems.
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Table 2. The predicted number of drugs at the index date and the predicted change in the number of drugs at the index date
compared with the preceding measure date.
Variables included in the model Number of drugs Change in number of drugs
Before After Before After
Model 1 Time 5.28 (5.25; 5.32) 7.31 (7.27; 7.35) 0.20 (0.17; 0.22) 0.02 (20.003; 0.05)
Model 2 Time
Diagnoses
5.59 (5.56; 5.62) 7.13 (7.09; 7.17) 0.21 (0.18; 0.23) 0.02 (20.002; 0.05)
Model 3 Time
Diagnoses
Healthcare contacts
5.57 (5.54; 5.60) 7.05 (7.01; 7.09) 0.12 (0.10; 0.15) 0.02 (20.004; 0.05)
Model 4 Time
Diagnoses
Healthcare contacts
Age
5.57 (5.34; 5.60) 7.05 (7.01; 7.09) 0.12 (0.10; 0.15) 0.02 (20.002; 0.05)
Model 5 Time
Diagnoses
Healthcare contacts
Age
Female sex
5.76 (5.71; 5.80) 7.15 (7.10; 7.19) 0.12 (0.09; 0.14) 0.02 (20.01; 0.05)
The parameter estimates are based on either data before or data after the index date. Values, given with 95% confidence limits within parentheses, represent parameter
estimates at the index date for an average individual, who had 10.8 unique ICD-10 diagnoses, 2.4 healthcare contacts during the three month period between the
measure dates, and a mean age of 83.2 years.
doi:10.1371/journal.pone.0067088.t002
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